|
Therapy for rheumatoid arthritis: unmet needs |
|
| Problem |
Details |
|
|
|
| Heterogeneity of the disease |
Some patients respond to DMARD monotherapy |
| Not every patient responds to anti-TNF (mono or combination) therapy |
|
| 'Remission' rates |
|
| What is the pathology/biologic process in each individual patient? |
|
| Toxicities |
Infections, immunogenecity, congestive heart failure, drug-induced vasculitis, etc |
| Costs |
Limits availability to may patients |
|
DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor. | |
Moreland Arthritis Research & Therapy 2005 7(Suppl 3):S2 doi:10.1186/ar1736 |
|